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Previous studies have shown that apolipoprotein B mRNA editing, enzyme catalytic, polypeptide G
(APOBEC3G; hA3G) and F (APOBEC3F; hA3F) proteins interact with a nonlinear binding site located at the
N-terminal region of the HIV-1 Vif protein. We have analyzed the role of 12 positively charged amino
acids of the N-terminal region of the SIV Vif. Simian-human immunodeﬁciency viruses (SHIV) were
constructed that expressed each of these amino acid substitutions. These viruses were examined for
replication in the presence of rhesus macaque APOBEC3 proteins (rhA3A–rhA3H), incorporation of the
different A3 proteins into virions, and replication in rhesus macaque PBMC. Similar to other studies, we
found that K27 was essential for rhA3G activity and rhA3F but was not important for restriction of
SHIVΔvif by rhA3A, rhA3D or rhA3H. Our results identiﬁed the arginine at position 14 of the SIV Vif as a
critical residue for virus restriction by rhA3D, rhA3G and rhA3H.
& 2013 Elsevier Inc. All rights reserved.
Introduction
Select members of the apolipoprotein B mRNA editing, enzyme
catalytic polypeptide 3 (APOBEC3; A3) gene family in primates
represent an innate host defense system that can inhibit the
replication of human immunodeﬁciency virus type 1 that does
not express a Vif protein (Chiu and Greene, 2008; Goila-Gaur and
Strebel, 2008; Harris et al., 2003; Jarmuz et al., 2002; Sheehy et al.,
2002). The A3 family in humans and rhesus macaques consists
seven members (A3A, A3B, A3C, A3D, A3F, A3G, and A3H) that are
tandemly arranged on chromosome 22 or 10, respectively. All
seven members either have one (A3A, A3C, A3H) or two (A3B, A3D,
A3F, A3G) canonical cytidine deaminase motifs (H-x-E-x23-28-P-C-
x2-4-C) (Betts et al., 1994; Dang et al., 2007; Jarmuz et al., 2002;
Schmitt et al., 2011; Wedekind et al., 2003; Xie et al., 2004).
Following the identiﬁcation of A3G (formerly CEM15) as a potent
inhibitor of the replication of Vif deﬁcient HIV-1 (HIV-1Δvif), it
was found that in the absence of Vif A3G is incorporated and
causes cytidine to uracil changes in the minus strand of single-
stranded DNA during reverse transcription, ultimately leading to
G-to-A mutations in the viral genome (Kao et al., 2003; Lecossier
et al., 2003; Mangeat et al., 2003; Sheehy et al., 2002; Yu et al.,
2004; Zhang et al., 2003). The Vif protein acts as an adapter that
binds the APOBEC3 proteins to the Cul5/ElonginB/C/rbx E3 ligase
complex for ubiquitination and degradation by the proteosome
(Conticello et al., 2003; Dussart et al., 2004; Kobayashi et al., 2005;
Liu et al., 2004; Marin et al., 2003; Mehle et al., 2004; Sheehy et al.,
2003; Stopak et al., 2003; Yu et al., 2003, 2004). In addition to A3G,
other A3 proteins have been shown to restrict the replication of
HIV-1Δvif. A3F is the most closely related protein to A3G at the
amino acid level and has a tissue distribution similar to A3G
(Wiegand et al., 2004; Zheng et al., 2004). When expressed
exogenously, hA3F is incorporated into and restricts the replication
of HIV-1Δvif virions, although the level of deamination is approxi-
mately 10 times less than A3G (Holmes et al., 2007; Wang et al.,
2007). A3F has been found to be expressed at lower levels in
human CD4þ T cells than A3G, causes less cytidine deamination of
Vif-deﬁcient HIV-1 and has less or no effect on its restriction
(Binka et al., 2012; Chaipan et al., 2013; Miyagi et al., 2010). A3B
has been reported to have moderate activity against HIV-1Δvif but
is expressed at low levels in natural HIV-1 cellular targets, so its
role in restriction of HIV-1 is uncertain (Doehle et al., 2005;
Refsland et al., 2010; Yu et al., 2004). A3D was also identiﬁed to
potently restrict HIV-1Δvif (Dang et al., 2007; Liddament et al.,
2004; Wiegand et al., 2004; Zheng et al., 2004). A3H has at least
seven haplotypes with haplotype II being able to potently restrict
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HIV-1Δvif and HTLV-I replication (Dang et al., 2008; OhAinle et al.,
2008; Ooms et al., 2010, 2012). A3A is neither incorporated into
the viral nucleocapsid nor does it restrict the replication of HIV-
1Δvif (Goila-Gaur et al., 2007). A3C is incorporated into the of HIV-
1 virion and has been reported to cause limited cytidine deamina-
tion while other studies indicate that it has no effect on virus
infectivity (Hultquist et al., 2011; Langlois et al., 2005).
Several domains have been identiﬁed in the N-terminal region of
the HIV-1 Vif that are involved in the interaction with several human
APOBEC3 proteins (Chen et al., 2009; Dang et al., 2007, 2010; Mehle
et al., 2007; Pery et al., 2009; Russell and Pathak, 2007; Wichroski
et al., 2005). Several studies that have used site-directed mutagenesis
to identify amino acid residues that are critical for Vif neutralization
of hA3G and hA3F. One study showed that deletion of amino acids
43–59 abolished interactions with A3G (Wichroski et al., 2005). In
another study, the use of overlapping peptides found that a region
from amino acids 33–88 formed a non-linear binding site for A3G
(Mehle et al., 2007). Additionally, amino acid residues 14–17 and 40–
44 were speciﬁcally found to effect the interactions with human A3F
and A3G, respectively (Russell and Pathak, 2007). Other investigators
showed that domains 23SLVx4Yx9Y38, 69YXXL72, 81LGxGxxIxW89 and
171EDRW174 were also involved in neutralizing hA3G and hA3F (Chen
et al., 2009; Dang et al., 2010; Pery et al., 2009).
The simian immunodeﬁciency virus (SIV) and simian-human
immunodeﬁciency virus (SHIV)/macaque models of infection have
been used extensively to study different aspects of lentiviral patho-
genesis and development of vaccines. Similar to the HIV-1 Vif, the SIV
Vif has comparable YXXL, SLQYLA and HCCH domains (Luo et al.,
2005; Pery et al., 2009; Schmitt et al., 2009, 2010; Yu et al., 2004).
However, the N-terminal region of the SIV Vif (and other regions) have
little sequence identity with the same region from the HIV-1 Vif,
making it difﬁcult to extrapolate ﬁndings to the Vif protein of SIV for
testing in vivo. The SIV Vif has a region containing several positively
charged amino acids that may be involved in electrostatic interactions
with different rhesus macaque A3 proteins. In this study, we analyzed
the importance of these positively charged residues on the exclusion
of different rhesus macaque APOBEC3 proteins (rhA3A-H) from virions
and on infectivity. We have identiﬁed a novel amino acid within the
SIV Vif that is important for restriction by rhA3D, rhA3G, and rhA3H.
Results
Expression and stability of the Vif mutants
Comparison of the amino acid sequence of the HIV-1 and
SIVmac Vif proteins show that there was 18% sequence identity at
the ﬁrst 50 amino acid positions (Fig. 1). To determine which
positively charged amino acids at the N-terminus of the protein
were critical to Vif function (i.e., virus replication in the presence
of the rhesus A3 proteins), we substituted the positively charged
residues at positions 5, 6, 14, 18, 21, 23, 27, 30, 32, 34, 38, and 46
to alanines (Fig. 1). First, we examined the stability of the Vif
mutant proteins in cells to insure that any observed effects on
virus restriction were not due to an unstable Vif protein. For
these experiments, an SIV Vif (human codon-optimized) with an
N-terminal 3X-Flag-tag was used. 293 cells were transfected with
vectors expressing each Vif protein for 48 h. Cells were radiolabeled
with 35S-methionine and the radiolabel chased for 0 and 6 h. The cells
were lysed and Flag-tagged proteins were immunoprecipitated using
a rabbit polyclonal anti-Flag antibody. The results of this experiment
showed that the twelve SIV Vif mutants were stable in 293 cells
similar to the unmodiﬁed SIV Vif at the 6 h time point (Fig. 2).
Replication of SHIVs expressing mutant Vif proteins
We constructed SHIV viral genomes expressing Vif proteins
with the amino acid substitutions in the N-terminal region as
described above. The SHIV used, SHIVKU-2MC4, has the tat, rev, vpu
and env from HIV-1 (HXBc2) in the background of SIVmac239 and
was derived from passage in rhesus macaques (Liu et al., 1999).
Virus stocks were prepared in SupT1 cells, which do not express
A3 proteins. Growth curves (based on p27 release) were estab-
lished for each virus in SupT1 cells and results indicate that all
viruses replicated in the SupT1 cells (Fig. 3A and B).
Incorporation of macaque rhA3A-H into SHIV, SHIVΔvif and SHIV vif
mutants into viral particles
To determine if the seven rhA3 proteins were incorporated into
SHIVΔvif, parental SHIVKU-2MC4, or SHIVs expressing the various
Vif mutants, 293 cells were co-transfected with plasmids that
expressed each of the tagged rhA3 proteins and each of the SHIV
genomes. At 24 h, the cells were radiolabeled and the culture
medium harvested at 36 h post-transfection. The virus was pur-
iﬁed by ultracentrifugation as described in Material and methods
section and immunoprecipitations were performed using an anti-
body against the HA-tag to determine if the A3 proteins were
incorporated into virions. We chose radiolabeling and immuno-
precipitations over immunoblots as they were more sensitive in
detecting A3 proteins. Our results indicate that rhA3B but not
rhA3C was incorporated into both SHIVΔvif and SHIVKU-2MC4
(Fig. 4A). Since rhA3B or rhA3C did not affect the replication of
SHIVΔvif and SHIVKU-2MC4 (see below in Table 1, we did not
1   50
HIV-1  MENRWQVMIVWQVDRMRINTWKRLVKHHMYISRKAKDWFYRHHYESTNPK
1   56            14    18   21 23     27  30 32 34     38           46
SIVmac239 MEEEKRWIAVPTWRIPERLERWHSLIKYLKYKTKDLQKVCYVPHFKVGWA
VifK5A ----A---------------------------------------------
VifR6A -----A--------------------------------------------
VifR14A -------------A------------------------------------
VifR18A -----------------A--------------------------------
VifR21A --------------------A-----------------------------
VifH23A ----------------------A---------------------------
VifK27A --------------------------A-----------------------
VifK30A -----------------------------A--------------------
VifK32A -------------------------------A------------------
VifK34A ---------------------------------A----------------
VifK38A -------------------------------------A------------
VifK46A ---------------------------------------------A----
Fig. 1. Alignment of the amino terminal 50 amino acids of the HIV-1 and SIV Vif proteins. Underneath the SIV Vif sequence, the mutants analyzed in this study are indicated in bold.
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proceed with incorporation studies. Our results indicate that
rhA3A was incorporated into SHIVΔvif but not SHIVKU-2MC4 or
any of the SHIVs expressing the mutants Vif proteins (Fig. 4B). We
found that rhA3D was incorporated into SHIVΔvif and SHIVVifR14A
and to a lesser extent in SHIVVifR6A and SHIVVifR21A; however, the
incorporation of rhA3D into SHIVs expressing the other Vif mutants
were comparable to SHIVKU-2MC4 (Fig. 4C). RhA3F was found to be
incorporated into SHIVKU-2MC4, SHIVΔvif, and to some extent in all
of the SHIVs expressing the mutant Vif proteins, while rhA3G was
incorporated into SHIVΔvif, SHIVVifR14A, and SHIVVifK27A (Fig. 4D and
E). Finally, rhA3H was incorporated into SHIVΔvif, and SHIVVifR14A in
signiﬁcant quantities (Fig. 4F). In summary, our results show that
rhA3D, G, and H were readily incorporated into SHIVVifR14A, and that
rhA3G was signiﬁcantly incorporated into SHIVVifK27A. As we have
previously reported, it is interesting to note that rhA3F was
incorporated into all viruses tested (Schmitt et al., 2010).
Restriction of replication of SHIVs expressing mutant Vif proteins in
the presence of the seven rhesus A3 proteins
We assessed the ability of the SHIVs expressing mutant Vif
proteins to replicate in the presence of the seven rhesus A3
proteins. For these studies, we used N-terminally HA-tagged
rhA3A-H and plasmids containing the SHIVKU-2MC4, SHIVΔvif, or
the different Vif mutants viral genomes. All experiments were
repeated at least six times and the mean shown in Table 1. Our
results indicate that rhA3A, rhA3B and rhA3C did not restrict the
replication of SHIVs containing the various Vif amino acid sub-
stitutions. Similar to previous studies, we found that the K27A
mutant replicated poorly (1% of control) in the presence of rhA3G
and in the presence of rhA3F (19% of control) but replicated well in
the presence of rhA3A, rhA3D, rhA3F, and rhA3H. This indicates
that the K27A mutation speciﬁcally resulted in sensitivity to rhA3G
and to lesser extent rhA3F. A salient ﬁnding of the study was that
rhA3D, rhA3G and rhA3H profoundly affected the replication of
SHIVVifR14A. We also observed that rhA3D effected the replication of
SHIVVifR6A and most of the Vif mutants with the exception of SHIVs
expressing K5A, R14A, R18A, K38A, and K46A. RhA3G was found
to effect the replication of two Vif mutants R14A, and K27A. It is
important to note that the effect of K27 substitution on virus
infectivity has previously been reported by other investigators
(Chen et al., 2009; Dang et al., 2010). Finally, rhA3H was found to
effect the replication of Vif mutants R14A, H23A, K30A, and K34A.
Replication of SHIVs expressing mutant Vif proteins in rhesus PBMC
We showed above that each of the viral genomes were capable
of replicating in SupT1 cells. Therefore, we determined if the
above Vif mutants were capable of replicating in rhesus PBMCs
(Fig. 5A and B). PBMCs were isolated, stimulated and then
inoculated with 104 TCID50 of virus for 4 h. The inoculum was
WT Vif Vector K5A R14A R18A R6A
0      6 0      6 0      60      60      60      6
R21A H23A K27A K32A K34AK30A
0      6 0      6 0      60      60      60      6 0      6 0      6
K38A K46A
Chase
Time
Chase
Time
Fig. 2. Expression of the different mutant Vif proteins. Vectors expressing each Flag-tagged Vif mutant were transfected into 293 cells for 48 h. The cells were starved for
methionine/cysteine and radiolabeled with 35S-methionine/cysteine for 60 min. The radiolabel was removed, the cells washed three times, and incubated in medium
containing cold excess methionine/cysteine for either 0 or 6 h. The cells were lysed in 1 RIPA buffer and the FLAG-tag containing Vif proteins immunoprecipitated with a
rabbit anti-Flag antibody. Panel A. Results of the pulse-chase analyses of cells transfected with vectors expressing the unmodiﬁed Vif, Δvif (ﬁrst 27 amino acids), VifK5A,
VifR6A, VifK14A, and VifR18A. Panel B. Results of the pulse-chase analyses of cells transfected with vectors expressing the VifK21A, VifH23A, VifK27A, VifK30A, VifK32A,
VifK34A, VifK38A, and K46A. The time of the chase in hours is indicated above each lane.
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Fig. 3. Replication of SHIVs expressing each Vif mutant in SupT1 cells. SupT1 cells
were inoculated with equivalent levels (25 ng) of SHIVKU-2MC4, SHIVΔvif, or viruses
expressing each of the mutant Vif proteins. At 4 h post-inoculation, the medium
was removed and replaced with fresh medium and incubated for 15 days. Replication
was assessed by the level of p27 in the medium at speciﬁc days post-inoculation. The
experiment was performed twice and p27 levels did not vary by more than 5%. Panel
A. Replication of SHIVKU-2MC4, SHIVΔvif, and SHIVs expressing Vif mutants R5A, K6A,
R14A, K18A, R21A, and H23A. Panel B. Replication of SHIVKU-2MC4, SHIVΔvif, and SHIVs
expressing Vif mutants K27A, K30A, K32A, K34A, K38A, and K46A.
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removed, cells washed, and then incubated in fresh medium
containing 50 ng of IL-2. Medium was removed every other day
for up to 15 days and analyzed for p27. The results of this
experiment are shown in Fig. 5A and B. The results indicate that
the mutants SHIVVifK5A, SHIVVifR6A, SHIVVifR18A, and SHIVVifR21A
replicated in rhesus PBMC to levels similar to the parental
SHIVKU-2MC4, while SHIVVifR14A and SHIVVifR27A and SHIVVifK30A
did not replicate to any signiﬁcant extent in rhesus PBMC
(Fig. 5A and B). Additionally, viruses such as SHIVVifH23A,
SHIVVifK32A, SHIVVifK34A, SHIVVifK38A, and SHIVVifK46A also replicated
in the rhesus PBMC but at reduced levels.
VifR14A binds less efﬁciently with rhA3D, rhA3G, and rhA3H while
VifK27A binds less efﬁciently with rhA3G
SHIVs expressing VifR14A incorporated rhA3D, G, and H into virus
particles whereas a SHIV expressing VifK27A had increased rhA3G
incorporated into virus particles. Therefore co-immunoprecipitation
rhA3B
Viral p27
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rhA3C rhA3G
rhA3
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rhA3
(cells)
vector
rhA3D
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Viral p27
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Viral p27
(medium)
rhA3G
(cell)
rhA3F
(cell)
rhA3H
(cell)
Viral p27
(medium)
rhA3H
(virus)
Fig. 4. The incorporation of A3 proteins into viruses expressing each of the mutant Vif proteins. 293 cells were transfected with a plasmids expressing rhesus macaque
tagged A3 proteins and genomes for SHIVKU-2MC4, SHIVΔvif, or the SHIVs expressing the different mutant Vif proteins. At 24 h post-transfection, the cells were starved for
methionine/cysteine and radiolabeled with 35S-methionine/cysteine for 12 h. The culture mediumwas collected and the virus partially puriﬁed as described in Materials and
methods section. The virus preparations were lysed in 1 RIPA buffer. Half of the samples were immunoprecipitated with an anti-HA or anti-V5 serum to detect the HA or
V5-tag containing A3 proteins while the other half immunoprecipitated with anti-SHIV serum to detect the p27 protein. Samples were normalized for equivalent amounts of
p27. A3 proteins were also immunoprecipitated from cell lysates with both anti-HA or anti-V5 serum and anti-SHIV sera to show that both A3 and SHIV proteins were
expressed in cells. For each panel, the upper gel represents the immunoprecipitation of A3 proteins from the cell lysates, the middle gel the A3 proteins in virus preparation
and the lower gel the immunoprecipitation of p27 protein from the same virus preparation. Panel A. RhA3B and rhA3C. Panel B. RhA3A. Panel C. RhA3D. Panel D. RhA3F.
Panel E. RhA3G. Panel F. RhA3H. The viral genomes or vectors transfected into cells are shown above the lanes.
Table 1
Infectivity of SIV Vif N-terminal mutants.a
Vif ΔVif K5A R6A R14A R18A R21A H23A K27A K30A K32A K34A K38A K46A
RhA3A 100 7n 86 44 90 47 44 76 86 100 78 46 93 88
RhA3B 100 100 79 80 66 100 76 100 100 100 100 95 100 100
RhA3C 100 91 100 63 60 100 53 100 100 100 48 70 70 62
RhA3D 100 2n 57 24n 0.7n 36 18n 48 100 66 75 35 92 93
RhA3F 100 7n 99 37 21n 100 14n 11n 19n 23n 13n 16n 100 84
RhA3G 100 4n 100 61 0.1n 100 57 77 1.0n 102 80 62 100 100
RhA3H 100 22n 65 100 1.0n 93 37 16n 79 25n 100 14n 98 70
a Infectivity of virus expressing the unmodiﬁed Vif was considered 100%. Those values that were statistically signiﬁcant are marked with an (n). Infectivity was
determined by transfection of 293 cells with a vector containing the viral genome and a vector expressing one of the rhA3 proteins, collecting virus at 48 h and assaying for
infectivity using the TZM.bl assay.
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experiments were used to determine if these Vif proteins still
interacted with rhA3D, G, and H. For these experiments, we used
Flag-tagged SIV Vif proteins (SIVVifwt, VifR14A, VifK27A, control
FLAG-tag vector, and a VifΔ17-50 in which amino acids 17–50 were
deleted and does not bind rhA3D,G, and H) and HA-tagged rhA3D,
rhA3G, or rhA3H proteins. Each of the Flag-SIV Vif proteins were co-
transfected with one of the rhA3 proteins into 293 cells. At 48 h, cells
were lysed in a non-ionic detergent, the Flag-tagged proteins
immunoprecipitated with an anti-Flag rabbit antibody, and the
complexes were collected on anti-rabbit coated magnetic beads.
The immunoprecipitates were analyzed for the presence of HA-
rhA3 proteins using an antibody against the HA-tag. Our results
indicated that wtVif readily co-immunoprecipitated rhA3G while
VifK27A and VifR14A co-immunoprecipitated signiﬁcantly less rhA3G
(Fig. 6). We also found that VifR14A co-immunoprecipitated less
rhA3D and H compared to wtVif. These results suggest that both of
these mutants interact less with rhA3G, rhA3D, and rhA3H.
VifR14A and VifK27A are incorporated into viral nucleocapsid
complexes in the presence of rhA3G
As the data above showed, rhA3D, G, and H interacted less with
VifR14A and VifK27A and interacted less with rhA3G. Next, we
determined if rhA3G was incorporated into the core at levels that
differed from the wild type Vif. At 48 h, the virus was collected
from the culture medium, pelleted and resuspended in either PBS
or PBS with 1% Triton X-100. Samples were loaded on a 20/60%
step gradient and subjected to ultracentrifugation for 6 h. On these
gradients intact virus was located at fraction 2 while the nucleo-
capsids were located in fraction 3. Fractions were collected,
divided into three samples and immunoprecipitated with appro-
priate antibodies against p27 (for viral Gag), HA (for A3 proteins),
and SHIV (for Env). As expected, cells transfected with vectors
expressing the SHIVΔvif genome and rhA3G had signiﬁcant rhA3G
incorporated into virions compared to cells transfected with
parental SHIVKU-2MC4 (Fig. 7A and B). Similar to SHIVΔvif, rhA3G
was detected in intact virus or nucleocapsid complexes (Triton-X-
100 treated virus) from cells transfected with vectors containing
the SHIVVifR14A or SHIVVifK27A genomes and rhA3G (Fig. 7C and D).
Thus, the pulldown experiments (Fig. 6) are in agreement with the
incorporation data (Fig. 7).
Discussion
Analysis of the N-terminal sequence of Vif from SIVmac239
(SIVsmm/HIV-2 group) and HIV-1 (SIVcpz/HIV-1 group) Vif reveals
little sequence identity (approximately 18%) between HIV-1 and
SIV Vif proteins at the N-terminus (Fig. 1). Having constructed a
full complement of HA-tagged rhesus macaque A3 proteins, we
asked if any of the positively charged residues at the N-terminus of
SIV Vif affected the anti-viral properties of the seven rhesus A3
proteins. We were especially interested in amino acids 27 to 38
that had ﬁve lysine residues spaced every two to four residues
(27KYLKYKTKDLQK38). Twelve site-directed mutants in the SIV Vif
were constructed and expressed in the context of simian-human
immunodeﬁciency virus (SHIV). Our studies here indicate that
SHIVs expressing Vif mutants K5A, R18A, K38A, and K46A had no
signiﬁcant effect on SHIVΔvif infectivity in the presence of the
seven rhA3 protein. We found that the other six Vif mutants
resulted in small reductions in infectivity that varied with the
rhA3 protein. Of these amino acids, R21A was common to four
rhA3 proteins and R6A was common to three A3 proteins. Our
results from these 10 mutants suggest that amino acids 6–34 may
form a surface that is involved in Vif interactions with rhA3D,
rhA3F, rhA3G, and rhA3H.
Two amino acids analyzed in this study, K27 and R14, had the
greatest impact on virus replication. Previous studies had shown
that the K26 residue of the HIV-1 and the K27 residue of SIV Vif
were critical for interaction with hA3G and its degradation (Chen
et al., 2009; Dang et al., 2009). Our results here conﬁrm this
ﬁnding as rhA3G was signiﬁcantly incorporated into SHIVVifK27A,
resulting in a 100-fold and 5-fold reduction in infectivity of this virus
in the presence of rhA3G and rhA3F, respectively. However, we found
that rhA3A, rhA3B, rhA3C, rhA3D, and rhA3H had no effect on the
infectivity on SHIVVifK27A. This emphasizes the key role that this
amino acid has on the interactions with human and rhesus A3G and
would explain its highly conserved nature among most SIV Vif
proteins (Chen et al., 2009). The ﬁnding that rhA3F was incorporated
into all of the virus mutants was not surprising as we previously
showed that rhA3F was incorporated into parental SHIVKU2MC4
(Schmitt et al., 2010). Our analysis of the replication of the 12 mutants
in rhesus PBMC suggests that both rhA3F and rhA3G were involved in
the virus restriction. The key mutant here was SHIVVifK30A, which did
not replicate in rhesus PBMC. The data suggest that that rhA3G was
not alone and sufﬁcient for virus restriction is based on our ﬁndings
that rhA3G did not restrict SHIVVifK30A in our 293 assays while rhA3F
restricted SHIVVifK30A 5-fold.
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Fig. 5. Rhesus macaque PBMC growth curves of SHIVs expressing Vif mutants.
Blood from uninfected naive rhesus macaques was used to isolate PBMC on Ficoll-
Hypaque gradients and stimulated for 2 days in medium containing Conconavlin A
(10 μg/ml) and IL-2 (50 ng/ml). The cells were washed three times, and the cells
were inoculated with equivalent levels of SHIVKU-2MC4, SHIVΔvif, or SHIVs expres-
sing each of the Vif mutants for 4 h. The cells were again washed to remove the
residual inoculum and incubated in fresh medium containing 50 ng/ml IL-2 for 15
days. Fresh medium was added every three days containing 50 ng/ml IL-2. Panel A.
Replication of SHIVKU-2MC4, SHIVΔvif, and SHIVs expressing the Vif mutants R5A,
K6A, R14A, R18A, R21A, and H23A. Panel B. Replication of SHIVKU-2MC4, SHIVΔvif,
and SHIVs expressing the Vif mutants K27A, K30A, K32A, K34A, K38A, and K46A.
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Previous studies showed that the substitution of the aspartic
acid and arginine residues at positions 14 and 15 of the HIV-1
Vif with alanines resulted in sensitivity to hA3F, hA3D, and
hA3H (Russell and Pathak, 2007; Zhang et al., 2008; Zhen et al.,
2010). A salient ﬁnding of our study was that a single amino acid
substitution in the SIV Vif, R14A, resulted in a 100-fold or
greater reduction in the infectivity in the presence rhA3D,
rhA3G, and rhA3H and a 5-fold reduction in infectivity in the
presence of rhA3F. Additionally, we found decreased interac-
tions of Vif14A with rhA3D, G, and H as determined using co-
immunoprecipitations. Comparison of the amino acid sequences
of the N-terminus of HIV-1 and SIV Vif reveal signiﬁcant
differences in this region. The HIV-1 Vif has an arginine (posi-
tion 15) in the context of 11WQVDRMRIK19 while the R14 of the
SIV Vif is ﬂanked by two proline residues (11PTWRIPER18). The
ﬁnding that the rhA3D, rhA3G, and rhA3H severely affected the
infectivity of SHIVVifR14A is a unique ﬁnding suggesting a central
role for this amino acid in the SIV Vif interactions with these
three rhesus A3 proteins. Recently, two groups demonstrated
that HIV-1 Vif (and SIV Vif) interact with the ubiquitously
expressed host cell protein known as core-binding factor sub-
unit beta (CBF-β), which is part of a heterodimeric core-binding
transcription factor (PEBP2/CBF). The CBF-β protein is important
for regulating host genes involved in hematopoeisis and osteo-
genesis (Jäger et al., 2011; Zhang et al., 2011). In one study, it
was shown that amino acids at the N-terminus of Vif were
important for binding to CBF-β, particularly the tryptophan
residues at positions 21 and 38 (Zhang et al., 2011). Therefore,
it will be of interest to determine if R14 is important in CBF-β
binding to the SIV Vif protein.
In another study that examined the importance of the HIV-1 Vif
K26 in restriction, investigators found decreased VifK26A interac-
tions with A3G based on the concentrations of the Triton-X-100
(0.1 versus 1.0%) used in co-immunoprecipitations (Chen et al.,
2009). In our studies with R14A and K27A proteins (Fig. 6) we
show that both Vif mutants were easily detected in our co-
immunoprecipitations using 1.0% Triton-X-100, which may reﬂect
different afﬁnities for the HIV-1 Vif/hA3G and SIV Vif/rhA3G
interactions.
The only studies performed to assess the role of Vif in vivo have
used either Vif-deleted SIV or SHIVs with the highly conserved
SLQYLA and HCCH domains mutated (Desrosiers et al., 1998;
Schmitt et al., 2009, 2010). We have recently constructed a novel
SHIV with the K27 deleted (SHIVVifΔK27), which like SHIVVifK27A is
restricted by rhA3G and to a much less extent by rhA3F. It will be
of interest to determine if inoculation SHIVVifΔK27 into macaques
results in persistent infections in the macaque. We envision
several possible scenarios. In the ﬁrst scenario, though unlikely,
inoculation of SHIVVifΔK27 into macaques could result in viral loads
and disease that is similar to the parental virus. In the second
scenario, if inoculated macaques develop no signiﬁcant CD4þ T
cell loss and have low or transient viral loads, we can conclude
that these two rhA3 proteins are all that is required for SIV/SHIV
restriction in vivo. In a third scenario, if inoculation of SHIVVifΔK27
into macaques results in moderate viral loads (and perhaps
associated with CD4þ T cell loss) it would suggest that tissue
reservoirs may exist for the virus where rhA3G and/or rhA3F are
not expressed or expressed at low levels. One possible reservoir for
this virus is the thymus. It is possible that A3G and A3F expression is
developmentally regulated during the differentiation of immature
thymocytes into CD4þ and CD8þ T cells. With pathogenic X4
SHIV, there is a near complete destruction of the thymus during
the initial weeks of infection (Joag et al., 1996). Previous studies have
shown that CXCR4 is expressed on double negative 1 (DN1) to double
positive cells (DP), representing many of the subsets of imma-
ture thymocytes, while CCR5 is generally expressed on maturing
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Fig. 6. Co-immunoprecipitation experiments reveal that VifR14A interacts with
rhA3D, rhA3G, or rhA3H and VifK27A interacts with rhA3G at reduced efﬁciencies.
293 cells were transfected with vectors pSIVVif, pSIVΔvif, pSIVVifR14A, pSIVVifK27A,
pSIVVifK38A, or pSIVVifΔ17-50 and vectors expressing HA-rhA3G, HA-rhA3D, or HA-
rhA3H. At 48 h post-transfection, the cells were washed and lysed in a buffer
containing 1% Triton X-100 for 30 min on ice and 30 min at room temperature. Cell
lysates were clariﬁed by centrifugation in a microfuge, and the complexes
immunoprecipitated using an anti-FLAG antibody on anti-rabbit IgG-coated mag-
netic Dynabeads (Life Technologies) overnight at 4 1C. The beads were washed
three times with the buffer containing 1% Triton X-100 for 5 min at 4 1C. The bound
proteins were boiled in 50 ml of 1 sample reducing buffer and proteins were
separated by SDS-PAGE. Western blot analysis was performed using a rabbit
polyclonal anti-HA primary antibody (sc-805, Santa Cruz Biotechnology) to detect
HA-tagged A3 proteins and a rabbit polyclonal anti-FLAG primary antibody (F7425,
Sigma) to detect the Vif proteins. The lysates containing the non-immunoprecipi-
tated proteins were collected and made 1 with sample reducing buffer, boiled
and subjected to Western blot analysis using anti-FLAG (for Vif) and anti-HA (for A3
proteins). For panels A–C, the upper blot represents the bound fractions co-
immunoprecipitated with the anti-FLAG antibody and detected with either the
rabbit polyclonal anti-FLAG antibody to detect the Vif proteins or the rabbit
polyclonal anti-HA antibody to detect the HA-A3 proteins, respectively.
The lower blot represents the unbound fractions from the co-immunoprecipitation
with the rabbit polyclonal anti-FLAG antibody and detected with either the rabbit
polyclonal anti-HA antibody for the HA-A3 proteins or the rabbit polyclonal anti-
FLAG for the Vif proteins. Panel A. Co-immunoprecipitation of VifR14A and VifK27A
with rhA3D. Panel B. Co-immunoprecipitation of VifR14A and VifK27A with rhA3G.
Panel C. Co-immunoprecipitation of VifR14A and VifK27A with rhA3H.
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CD4þ CD8-subsets (Ara et al., 2003; Plotkin et al., 2003; Trampont
et al., 2010). Thus, it will be of interest to determine if SHIVVifΔK27 can
replicate in one or more subsets of thymocytes during differentiation.
While it seems intuitive that the ﬁrst scenario is most likely, it has
not been formally shown in vivo.
Materials and methods
Cells, plasmids, and viruses
The C8166, and SupT1 lymphocyte cell lines were used for
transfections and as indicator cells to measure infectivity and
cytopathicity of the viruses used in this study. Both cell lines were
maintained in RPMI-1640, supplemented with 10mM Hepes buffer
pH 7.3, 2 mM glutamine, 5 μg/ml gentamicin and 10% fetal bovine
serum (R10FBS). 293 and TZM.bl cells were used for transfections
and as an indicator cell line for infectivity assays, respectively
(Platt et al., 1998, 2009; Takeuchi et al., 2008; Wei et al., 2002;
Derdeyn et al., 2000). Rhesus PBMC were isolated from SIV/SHIV-
negative donors on Ficoll-Hypaque gradients. The derivation of
SHIVKU-2MC4 has been previously described (Liu et al., 1999). The
plasmid expressing rhA3A has been previously reported (Genbank
accession JF831054; Schmitt et al., 2011). For expression of the
rhesus C (Genbank accession EU381233), D (Genbank accession
JF714488), and H (Genbank accession DQ507277) proteins, genes
were synthesized by GenScript and subcloned into the pcDNA3.1
(þ) vector with HA-tags at N-terminus. The rhA3B was based on
our analysis of the from the rhesus macaque genome, was
synthesized by GenScript and cloned into pcDNA3.1(þ). Sequence
analysis shows that this rhA3D clone has an aspartic acid at
position 316, which was recently shown to be important for
restriction of HIV-1 (McDougle et al., 2013). The pcDNA3.1
(þ)-rhA3G-HA and pcDNA3.1(þ)-rhA3F-V5 were kindly provided
by Nathaniel Landau (New York University of School of Medicine,
New York, NY). All stocks of APOBEC3 plasmids were prepared by
growing bacteria at 30 1C.
The stability of the Vif mutant proteins
The stability of the engineered mutations in the human codon-
optimized SIV Vif were assessed by transfecting 293 cells in a
6 well plate with 3 μg of vectors expressing p3xFLAG-Vif,
p3xFLAG-ΔVif, p3xFLAG-VifK5A, p3xFLAG-VifR6A, p3xFLAG-
VifR14A, p3xFLAG-VifR18A, p3xFLAG-VifR21A, p3xFLAG-VifH23A,
p3xFLAG-VifK27A, p3xFLAG-VifK30A, p3xFLAG-VifK32A, p3xFLAG-
VifK34A, p3xFLAG-VifK38A, or p3xFLAG-VifK46A using TurboFect
(Fermentas) and the manufacturer's instructions. After 48 h, the
cells were starved for 2 h in medium without methionine/cysteine
and then radiolabeled with 300 μCi (per well) of 35S-methionine/
cysteine for 1 h. The cells were then chased for 0 and 6 h. At these
time points, the cells were lysed in 1 RIPA and the nuclei
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Fig. 7. Incorporation of rhA3G into the nucleocapsids of SHIVKU-2MC4, SHIVΔvif, SHIVVifR14A and SHIVVifK27A. 293 cells were transfected with plasmids containing the viral
genomes (SHIVVifR14A, SHIVVifK27A, SHIVΔvif, or SHIVKU-2MC4) and rhA3G. At 24 h, the cells were starved and radiolabeled with 35S-methionine/cysteine for 24 h. The culture
mediumwas harvested, and the virus concentrated using ultracentrifugation. The virus was then subjected to ultracentrifugation on sucrose step gradients and fractions S1-
S4 collected as described in Materials and methods. Each fraction was analyzed for the presence of rhA3G (upper gel), p27 (middle gel) and envelope gp120 (lower gel).
Panel A. SHIVKU-2MC4. Panel B. SHIVΔvif. Panel C. SHIVVifR14A. Panel D. SHIVVifK27A.
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was removed by centrifugation. The Flag-tagged proteins were
immunoprecipitated using a rabbit polyclonal antibody (Sigma-
Aldrich, St. Louis, MO) overnight at 4 1C. The samples were
resuspended in 2 sample buffer, boiled for 5 min, run on a
12%-SDS PAGE gel, and visualized by autoradiography.
Construction of SHIVs with amino acid substitutions in the SIV Vif
protein
For the construction of various SHIVs expressing mutant Vif
proteins, the PacI/SphI fragment (nucleotides 4609–5901) from
the p5′-SHIV4 was subcloned into the pSI vector at Pac I and Sph I
sites. Oligonucleotide site-directed mutagenesis was used to
change the following amino acids to alanines: K5, R6, R14, R18,
R21, H23, K27, K30A, K32, K34, K38, and K46. All substitutions
were made using the Quick-Change Mutagenesis Kit (Stratagene)
following the manufacturer's instructions. The resulting PacI/SphI
fragment was digested, isolated, and subcloned into full length
SHIVKU-2MC4 (Liu et al., 1999). The resulting plasmid was
sequenced to ensure that the desired mutations were introduced
as expected. The full-length plasmids with the K5A, R6A, R14A,
R18A, R21A, H23A, K27A, K30A, K32A, K34A, K38, and K46
mutations were designated as SHIVVifK5A, SHIVVifR6A, SHIVVifR14A,
SHIVVifR21A, SHIVVifH23A, SHIVVifK27A, SHIVVifK30A, SHIVVifK34A, SHIV-
VifK38A, and SHIVVifR46A, respectively. Plasmids with full length
genomes were transfected into SupT1 cells using procedures
previously described and stocks of each virus were prepared,
titered on SupT1 cells, and stored at 86 1C (Hout et al., 2004,
2005; Stephens et al., 2002). The construction of SHIVΔvif has
been previously described (Schmitt et al., 2010). The preparation
and titration of this viral stock was the same as described above.
The full-length plasmid was transfected into SupT1 cells as
described above, stocks prepared, titered on SupT1 cells, and
stored at 86 1C.
Analysis of the replication of Vif mutants in SupT1 cells and macaque
PBMC
SupT1 (A3G/F negative) cells were inoculated with equivalent
levels (25 ng) of parental SHIVKU-2MC4, each SHIV expressing a Vif
mutant, or SHIVΔvif for 4 h at 37 1C. At 4 h, cells were centrifuged,
washed 3 times to remove the inoculum and incubated in fresh
medium at 37 1C for up to 15 days. Aliquots of culture supernatants
were obtained at 0, 1, 3, 5, 7, 9, 11, 13, and 15 days post-inoculation
and the levels of p27 assessed using commercial p27 antigen
capture kits (Zeptometrix).
We also assessed the replication of SHIVKU-2MC4, the various
SHIVs expressing mutant Vif proteins, or SHIVΔvif in rhesus PBMC.
For replication in rhesus macaque PBMC cultures, blood was
obtained from uninfected rhesus macaques, and the PBMC sepa-
rated on Ficoll-Hypaque gradients. The PBMC were stimulated in
Con A (10 μg/ml) and IL-2 (50 ng/ml) for 48 h. The cells were
washed three times and inoculated with 25 ng of virus for 4 h at
37 1C. The inoculum was washed off and the cells incubated in
medium containing 50 ng/ml of IL-2. Aliquots of culture super-
natants were obtained at 0, 1, 3, 5, 7, 9, 11, 13 and 15 days post-
inoculation and the levels of p27 released into the culture medium
assessed using commercial p27 antigen capture kits (Zeptometrix).
SHIV restriction assays
SHIV, SHIVΔvif, or the mutant SHIVs (1 μg) described above
were co-transfected with plasmids expressing rhA3A, rhA3B,
rhA3C, rhA3D, rhA3F, rhA3G, or rhA3H (0.5 μg) using PEI (Fermen-
tas) in a 12-well plate. At 48 h post-transfection, the culture
medium was harvested and clariﬁed by low speed centrifugation.
Equivalent amounts of p27 were serially diluted using 10-fold
dilutions from 101–106 and used to inoculate TZM-bl cells in a 96
well plate. At 48 h post-inoculation, the media was removed, the
cells were washed with 1 PBS (pH 7.4), and the monolayer was
ﬁxed using 1% formaldehyde–0.2% glutaraldehyde in 1 PBS. The
cells were washed three times and incubated in a solution
containing 4 mM potassium ferrocyanide, 4 mM potassium ferri-
cyanide, 4 mMmagnesium chloride, and 0.4 mg of X-gal per ml for
2 h at 37 1C. The reaction was stopped and the infectious units (IU)
per ml were calculated (Derdeyn et al., 2000; Wei et al., 2002).
All samples were run at least in triplicate.
RhA3 protein incorporation assays
We determined if the seven rhA3 proteins were incorporated
into the various SHIVs expressing the different Vif mutants.
Plasmids of viruses (derived from SHIVKU-2MC4) expressing each
of the mutant Vif proteins described above were used to transfect
293 cells along with plasmids expressing either HA-tagged rhA3A,
B, C, D, F, G, or H. At 36 h post-transfection, cells were starved for
2 h in mediumwithout methionine/cysteine and then radiolabeled
with 300 μCi (per well) of 35S-methionine/cysteine for 12 h. At
24 h, virus containing supernatants were harvested and clariﬁed
by low speed centrifugation. The clariﬁed supernatant was then
subjected to ultracentrifugation to pellet the virus (SW41 rotor,
38,000 rpm, 1 h, 4 1C). The pellet was resuspended in PBS (pH 7.4)
and layered on a 20/60% sucrose step gradient and again subject to
ultracentrifugation (SW55Ti, 38,000 rpm, 1 h). The virus (at the
interface) was harvested, pelleted again by ultracentrifugation
described above, and resuspended in 200 μl of 1 PBS (pH 7.4).
An aliquot was saved to determine p27 content by commercial
antigen capture assays and the remaining sample divided in half
and immunoprecipitated overnight at 4 1C with either anti-SHIV
to detect the viral proteins or a rabbit polyclonal HA antibody
(sc-805; Santa Cruz) to detect HA-rhA3G, D, C, B, and H or a mouse
monoclonal V5 antibody (Sigma-Aldrich) to detect V5-rhA3F.
The samples were resuspended in 2 sample buffer, boiled for
5 min, run on a 12% SDS-PAGE gel, and visualized by autoradio-
graphic techniques. All samples were loaded using equivalent
amounts of p27. The cells were lysed in 1 RIPA, the nuclei
were removed by centrifugation, the lysates were divided in half,
and the samples were probed for either the HA or V5-tagged A3
proteins or with anti-SHIV to detect the p27 protein as described
above.
Co-immunoprecipitation experiments
We determined of the SIV Vif and various Vif mutants would
co-immunoprecipitate rhA3G, rhA3D, or rhA3H. 293 cells were
transfected with 2 μl of p3XFLAG-SIVVif, p3XFLAG-SIVΔvif,
p3XFLAG-SIVVifR14A, p3XFLAG-SIVVifK27A, p3XFLAG-VifK38A,
p3XFLAG-SIVVifK46A, or p3XFLAG-SIVVifΔ17-50 and 6 ml of either
pHA-rhA3G, pHA-rhA3D, or pHA-rhA3H. At 24 h post-transfection,
the cells were washed in cold 1 PBS and lysed in buffer (50 mM
Tris–HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100,
protease inhibitor cocktail) for 30 min on ice and 30 min at room
temperature. Cell lysates were cleared by centrifugation at
16,000 g at 4 1C for 10 min. The resulting supernatants were
added to anti-rabbit IgG-coated magnetic Dynabeads (Invitrogen
Dynal, Oslo, Norway) and immunoprecipitated with rabbit anti-
FLAG antibody (Sigma-Aldrich) overnight at 4 1C. The beads
were washed three times with buffer (50 mM Tris–HCl, pH 7.4,
250 mM NaCl, 1 mM EDTA, 1% Triton X-100, protease inhibitor
cocktail) for 5 min at 4 1C. The bound proteins were eluted with
50 ml of 1 sample reducing buffer (63 mM Tris–HCl, pH6.8, 10%
glycerol, 2% SDS, 0.0025% bromophenol blue) and boiled for 5 min.
K. Schmitt et al. / Virology 449 (2014) 140–149 147
The proteins were separated by SDS-PAGE and subjected to
Western blot analysis to detect the HA-tagged A3 proteins using
a rabbit polyclonal anti-HA primary antibody (sc-805, Santa Cruz)
and the Vif proteins detected using a rabbit polyclonal anti-FLAG
antibody (F7425, Sigma-Aldrich). The lysates containing the non-
immunoprecipitated proteins were collected and made 1 with
sample reducing buffer, boiled, and subjected to Western blot
analysis for A3 and Vif proteins as described above.
The incorporation of rhA3G into the viral nucleocapsids
In order to assess the incorporation of rhA3G proteins in the
NPC, 293 cells seeded into a 6-well plate and transfected with a
vector expressing rhA3G (3 μg/well) for 24 h. The cells were then
transfected with SHIVΔvif and vectors expressing either p3xFLAG-
SIV-Vif, p3xFLAG-SIVVifR14A, p3xFLAG-SIV-VifK27A, or p3xFLAG-
SIVΔVif for an additional 24 h. The cells were then starved for
methionine/cysteine for 2 h and radiolabeled with 300μCi of 35S-
methionine/cysteine for an additional 24 h. The virus-con-
taining supernatants were harvested, cleared by low speed cen-
trifugation, and concentrated by pelleting the virus through a 20%
sucrose cushion using ultracentrifugation (SW41 rotor, 247,000xg,
1 h, 4 1C). The concentrated viral pellets were resuspended in 1
PBS (pH 7.4) and used on sucrose step-gradients with or without
Triton-X-100. The sucrose step gradients were prepared as follows:
2.0 ml of a 60% sucrose solution (w/v, in 1 PBS) was placed into
the bottom of a SW55Ti ultracentrifuge tube and overlaid with
2.0 ml of a 20% sucrose solution (w/v, in 1 PBS). Immediately
prior to the addition of concentrated virus stocks, the step
gradients were overlaid with 100 μl of either 1 PBS or 1%
Triton-X-100 in 1 PBS. This procedure minimized the amount
of time the detergent was exposed to the virions. Samples were
then centrifuged in a SW55Ti rotor (247,000 g for 6 h at 4 1C).
Four fractions of 1.0 ml each were collected from the top of the
gradient with fraction 1 containing soluble proteins, fraction 2 a
buffer of 20% sucrose that separates soluble proteins from the viral
particles or viral cores, fraction 3 that includes the interphase of
20%:60% sucrose where viral particles and viral cores accumulate,
and fraction 4 containing the 60% sucrose fraction. Gradient
fractions were divided in halves or thirds, diluted to 1 ml with
1 RIPA buffer and subjected to immunoprecipitation assays
using an HA-speciﬁc antibody (sc-805, Santa Cruz) for the A3
proteins, a Flag-speciﬁc antibody (F7425, Sigma-Aldrich) for the
Vif protein or anti-SHIV serum for the capsid and matrix proteins.
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